Anzeige
Mehr »
Freitag, 19.06.2026 - Börsentäglich über 12.000 News
Batterie-Boom: Ein 78-Mio.-CAD-Schwergewicht greift nach Tiefsee-Rohstoffen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
738 Leser
Artikel bewerten:
(2)

Zifo Technologies: Zifo highlights New Everest Group Report showcasing critical need for science-first IT delivery

CAMBRIDGE, Mass. and CAMBRIDGE, England, March 19, 2026 /PRNewswire/ -- Zifo, the global leader in AI and data-driven informatics for science-driven organizations, highlights the release of a new Everest Group research report: 'Embedding Scientific Expertise at the Core of Life Sciences IT Service Delivery'. The report's central finding is straightforward: digital transformation in biopharma and other science-focused industries only works if scientific accuracy is baked into the AI and tech process from day one.

For years now, biopharma and other science-driven industries have faced a subtle disconnect: scientific breakthroughs are happening faster than ever, but the informatics supporting them haven't kept pace. The way organizations build, deploy, and manage scientific informatics systems lags scientific breakthroughs, with legacy data handling and processes remaining mostly unchanged.

The current AI boom makes this problem more obvious. Generic technology platforms promise speed and efficiency, but they usually stumble when faced with the highly complex workflows that scientists rely on. Simply put, Zifo believes that if an organization's process, data and technology doesn't understand the basic language of biology, chemistry, or physics, it won't deliver useful results.

Everest Group's research backs this up. The report shows that even the most advanced AI models and data architectures will fail if they aren't deeply tied to scientific reality. It's no longer enough for IT partners to just know tech -- they have to understand the science, too. Integrating scientific expertise into process, data, and organizational changes is what actually drives business value.

Treating Science IT like generic corporate IT creates massive enterprise risks. When systems are built on standard business logic rather than specific scientific context, companies run into several major roadblocks:

  • Compliance exposure: Blackbox nature of AI models can lead to compliance breaches and long-term reputational consequences with regulators.
  • Outcome risks: Inconsistent decisions in clinical trials and unpredictable manufacturing quality.
  • Loss of trust: Scientists, clinicians, and regulators losing faith in the digital platforms.
  • Reputational damage: The fallout from publishing flawed or unsubstantiated results.
  • Wasted investments: Low user adoption rates and expensive AI pilots that fail to scale.
  • Scaling failures: Lack of scientific domain depth in AI pilots can lead to organizations facing an accumulation of stalled PoCs and poor ROI.

While you don't necessarily need deep scientific context for every single back-office IT operation, it becomes critical in areas with high complexity and strict regulations. According to the report, companies saw the most value from embedding scientific expertise in drug discovery and research (77%), clinical development (73%), and manufacturing operations (37%). Because of this clear ROI, nearly 8 in 10 pharma leaders say scientific expertise will be a major deciding factor with 4 in 10 already viewing it as a key future differentiator.

To help companies make this transition, the report outlines a practical, four-step blueprint for scaling a science-first digital strategy:

  1. Assess: Look at your current operations to see how deeply science is currently integrated and figure out your starting point.
  2. Embed: Set up the right data and governance foundations to support science-driven IT execution.
  3. Scale: Build hybrid delivery teams that seamlessly combine strong tech skills with actual scientific backgrounds.
  4. Institutionalize: Make this science-first approach the standard way of operating across the entire company.

To read the Everest Group report, please click here: https://zifornd.com/scientific-it-service-delivery-everest-whitepaper/

About Zifo

Zifo is the leading global enabler of AI and data driven enterprise informatics for science driven organizations. With extensive solutions and services expertise spanning research, development, manufacturing, and clinical domains, we serve a diverse range of industries, including Pharma, Biotech, Chemicals, Food and Beverage, Oil & Gas, and FMCG. Trusted by over 190 science-focused organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation. https://zifornd.com/; https://zifornd.com/practical-ai-blueprints/

Logo: https://mma.prnewswire.com/media/2731415/5873188/Zifo_Technologies_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/zifo-highlights-new-everest-group-report-showcasing-critical-need-for-science-first-it-delivery-302718675.html

© 2026 PR Newswire
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.